Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial The findings, presented today at the 2023 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results